Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 330

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 330
---
 in this offering. We do not know how long the Selling Shareholder will hold the shares before selling them,
and we currently have no agreements, arrangements or understandings with the Selling Shareholder regarding the sale of any of the shares.

Beneficial ownership is determined
in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which
the Selling Shareholder have voting and investment power. The percentage of Ordinary Shares beneficially owned by the Selling Shareholder
following the offering shown in the table below is based on an aggregate of 6,685,918,922 Ordinary Shares outstanding on January 15, 2025.
Because the purchase price of the Depositary Shares issuable under the Purchase Agreement is determined on each Fixed Purchase Date, with
respect to a Fixed Purchase, on the applicable VWAP Purchase Date, with respect to a VWAP Purchase, and on the applicable Additional VWAP
Purchase Date, with respect to an Additional VWAP Purchase, the number of shares that may actually be sold by us to the Selling Shareholder
under the Purchase Agreement may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale
of all of the shares offered by the Selling Shareholder pursuant to this prospectus.

We may amend or supplement
this prospectus from time to time in the future to update or change the Selling Shareholder list and the securities that may be resold.

Please see the section titled
“Plan of Distribution” for further information regarding the Selling Shareholder’s method of distributing these
securities.

| Name of Selling Shareholder     |     | Number of Ordinary 
 Shares Owned Prior 
 to                 
 Offering (1)       |     | Maximum Number of  
 Ordinary Shares to 
 be Sold            
 Pursuant to this   
 Prospectus         |                 |     | Number of          
 Ordinary           
 Shares Owned After 
 Offering (2)       |     | Percentage   
 of           
 Ordinary     
 Shares       
 Owned        
 after the    
 Offering (3) |
| C/M Capital Master Fund, LP (4) |     | --                 |     |                    | 358,750,000,000 |     | --                 |     | --           |

__________________

| (1) | In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially                             
 owned prior to the offering all of the shares that the Selling Shareholder may be required to